For most of his career, Joël Le Bon studied how organizations create better outcomes through smarter systems.
A professor of marketing at the Johns Hopkins Carey Business School, Le Bon built an international reputation researching and teaching the intersection of sales, marketing, competitive intelligence, and commercialization strategy. His work explored how information flows through organizations, how opportunities are identified, and how success can be engineered rather than left to chance.
Then, in the fall of 2024, a cancer diagnosis changed everything.
The diagnosis was devastating, but it also forced Le Bon to confront a question he had spent years examining from a different angle: What role does luck play in life-changing outcomes?
Today, that question has become the driving force behind a new chapter of his scholarship—one inspired not only by his academic interests, but by his own survival.
Referring to Hopkins’ “Research Saves Lives” campaign, Le Bon wrote “Research saves lives, including mine,” in a LinkedIn post reflecting on his experience.
His cancer was detected at stage 2, early enough for treatment to significantly improve his prognosis. Looking back, he recognizes how many fortunate circumstances contributed to that outcome.
“I felt lucky,” he said. “At stage 2, I felt like I had been given a second chance.”
He was fortunate to have access to world-class care through Johns Hopkins. He was fortunate to have an oncologist who pushed for additional testing. He was fortunate that warning signs were identified when there was still time to act.
Those experiences led him to an unsettling realization: not everyone receives the same opportunities, and differences in outcomes often reflect differences in the systems that create, distribute, and support those opportunities.
For years, Le Bon researched and taught how sales and marketing systems work together to create, distribute, and convert opportunities into commercial outcomes. Following his diagnosis, he began asking a parallel question in healthcare: If luck plays a role in early cancer detection—and it clearly does— what does that reveal about how healthcare systems create and distribute opportunities for detection, and how can those systems reduce the need for luck in the first place?
That question now sits at the center of his emerging research agenda.
From “lucky salespeople” to lucky patients
The transition was not as abrupt as it might appear.
Long before his cancer diagnosis, Le Bon had been fascinated by luck, serendipity, and the conditions that make positive outcomes more likely. In fact, he incorporated those ideas directly into his teaching.
One of his courses challenged students to think differently about success. He would ask questions such as: Do you believe in luck? Does luck believe in you? Would you want others to attribute your achievements to luck?
His research and writing explored similar themes. Rather than viewing luck as pure chance, Le Bon became interested in how individuals and organizations can create conditions that increase the likelihood of favorable outcomes.
He refers to this concept as the “engineering of serendipity.”
Now, that framework is helping him examine healthcare through a new lens, viewing early detection as a system of opportunities that can either be recognized, missed, or unequally distributed across populations.
Le Bon distinguishes between accidental luck and what he calls “provoked” luck—outcomes that may appear fortunate but are actually made possible through proactive systems, behaviors, and decisions.
Applied to healthcare, the concept raises important questions. If some cancer diagnoses happen early because patients have access to better information, better screening, better physicians, or better healthcare infrastructure, can those advantages be systematically extended to more people?
And if they can, why aren’t they?
“The existence of luck in healthcare,” Le Bon argues, “suggests that some people have access to opportunities that others do not.”
His research increasingly focuses on understanding those disparities and identifying ways to design healthcare systems that make positive outcomes less dependent on chance and more dependent on equitable access, responsiveness, and opportunity.
The goal is not to eliminate luck entirely. Rather, it is to create healthcare systems so effective that luck becomes less necessary.
Finding meaning in adversity
Le Bon’s cancer diagnosis came during an already difficult period in his life.
Just before learning he had cancer, he lost his father.
The timing was painful, but it also reinforced a perspective that has become central to both his personal outlook and his academic work.
Growing up, Le Bon’s father often told him to “look on the bright side.”
After his diagnosis, Le Bon adapted that advice into a personal philosophy: “Look on the bright side—and luck on the bright side.”
For him, that means actively identifying the fortunate elements that exist even within difficult circumstances.
In his own case, he points to several.
He feels fortunate that his father was spared the pain of learning his son had cancer. He feels fortunate to be part of the Johns Hopkins ecosystem. He feels fortunate to have received exceptional care from clinicians and researchers dedicated to improving patient outcomes.
Rather than minimizing the seriousness of cancer, the mindset helps him focus on gratitude, resilience, and possibility.
For Le Bon, the experience inspired a re-mission: a renewed commitment to understanding how healthcare systems can create more opportunities for early detection and better outcomes. It also renewed his sense of purpose in his research and work.
It has also strengthened his belief that healthcare innovation should not only cure disease but create pathways to earlier detection and intervention.
A new research mission
Le Bon’s scholarly productivity since his diagnosis reflects the depth of that commitment.
In roughly a year, he has prepared research for five academic conferences, developing new ideas around preventive health, healthcare systems, and the role of luck in medical outcomes.
The work represents a significant evolution for a scholar whose previous research focused primarily on commercialization strategy, revenue operations, and the coordination of marketing and sales systems. Yet the underlying theme remains remarkably consistent.
Throughout his career, Le Bon has studied how systems influence outcomes.
Whether examining how companies identify market opportunities or how healthcare providers identify early signs of disease, he is ultimately interested in the same challenge: understanding why some opportunities are recognized and acted upon while others are missed, delayed, or never encountered at all.
His current work asks whether healthcare systems can be designed to recognize critical diagnostic opportunities earlier, more consistently, and more equitably, reducing unnecessary dependence on luck in the process. It examines how data, technology, institutional structures, governance arrangements, and human decision-making interact to shape life-altering outcomes.
In many ways, his personal experience transformed an intellectual interest into a deeply personal mission.
Research, after all, did more than inspire his latest scholarly pursuits. It saved his life.
Encouragement from colleagues, clinicians, reviewers, and fellow researchers reinforced his belief that these questions were worth pursuing and might help advance important conversations about early detection and health equity.
And now, Le Bon hopes his work will help create a future in which fewer people must rely on luck to receive the same chance he was given, and where healthcare systems are evaluated not only by how they treat disease, but also by how effectively they create health opportunities.
As he continues exploring what he calls the engineering of serendipity, his central question remains both simple and profound: If we know that luck influences health outcomes, what can we do to make sure everyone has a better chance?
